Mometasone and Markers of Airway Inflammation

Creighton University

Status and phase: Completed; Phase 4

Conditions: Asthma

Treatments: Drug: Placebo; Drug: Mometasone Furoate

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00711165

Mometasone TBC

Details and patient eligibility

About

A post-marketing study to look at the effects of Asmanex on markers of airway inflammation.

Full description

Patients with asthma and not treated with anti-inflammatory medications were studied. This was a parallel, randomized, placebo-controlled study to investigate the effects of Asmanex on markers of airway inflammation including exhaled nitric oxide, airway reactivity, FEV1 and nitrates/nitrites and pH in exhaled breath condensate.

Enrollment: 12 patients

Sex: All

Ages: 19 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Asthma
• non-smoker
• FEV1 of at least 60% predicted

Exclusion criteria

• Pregnancy or lactation
• Corticosteroid use in past 30 days

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

12 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo, 2 puffs, bid

Treatment:

Drug: Placebo

Memetasone

Experimental group

Description:

Mometasone

Treatment:

Drug: Mometasone Furoate